These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9226103)

  • 41. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
    Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
    J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The pharmacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjects.
    Thomas M; Keery RJ; Charter MK; Scully NL; Chilton JE; Lumley P
    Br J Clin Pharmacol; 1991 Aug; 32(2):181-6. PubMed ID: 1834144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
    Vilahur G; Casaní L; Badimon L
    Thromb Haemost; 2007 Sep; 98(3):662-9. PubMed ID: 17849057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis.
    Schumacher WA; Heran CL; Steinbacher TE; Youssef S; Ogletree ML
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):526-33. PubMed ID: 7505353
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential involvement of serotonin 2A/C and thromboxane A2/prostanoid receptors in high- vs. low-shear rate arterial thrombosis in rabbits.
    Valentin JP; Vieu S; Bertolino F; Fauré P; John GW
    J Pharmacol Exp Ther; 1997 Feb; 280(2):761-9. PubMed ID: 9023289
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
    Rolin S; Petein M; Tchana-Sato V; Dogne JM; Benoit P; Lambermont B; Ghuysen A; Kolh P; Masereel B
    J Pharmacol Exp Ther; 2003 Jul; 306(1):59-65. PubMed ID: 12721335
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
    Schumacher WA; Lucchesi BR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):790-6. PubMed ID: 6418881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.
    Soyka R; Heckel A; Nickl J; Eisert W; Müller TH; Weisenberger H
    J Med Chem; 1994 Jan; 37(1):26-39. PubMed ID: 8289199
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Experimental coronary artery thrombosis in the absence of thromboxane A2 synthesis: evidence for alternate pathways for coronary thrombosis.
    Hook BG; Schumacher WA; Lee DL; Jolly SR; Lucchesi BR
    J Cardiovasc Pharmacol; 1985; 7(1):174-81. PubMed ID: 2580139
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Depin JC; Vigié A; Chavernac G; Rousselot C; Lardy C; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1203-7. PubMed ID: 7848332
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of thromboxane (TX) A2 in rabbit arterial thrombosis induced by endothelial damage.
    Imura Y; Terashita Z; Nishikawa K
    Thromb Res; 1990 Jul; 59(1):195-205. PubMed ID: 2119075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death.
    Kitzen JM; Lynch JJ; Uprichard AC; Venkatesh N; Lucchesi BR
    Pharmacology; 1988; 37(3):171-86. PubMed ID: 3227051
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
    Tubaro E; Belogi L; Mezzadri CM
    Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
    Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
    J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of thrombus formation by endothelin-1 in canine models of arterial thrombosis.
    Leadley RJ; Humphrey WR; Erickson LA; Shebuski RJ
    Thromb Haemost; 1995 Dec; 74(6):1583-90. PubMed ID: 8772241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries.
    Tanaka T; Morishima Y; Watanabe K; Takahashi M; Shibano T
    Methods Find Exp Clin Pharmacol; 1995 Dec; 17(10):693-700. PubMed ID: 9053590
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade.
    Golino P; Ambrosio G; Gresele P; Pascucci I; Ragni M; Russolillo E; Leproux GB; Chiariello M
    J Pharmacol Exp Ther; 1993 Aug; 266(2):511-7. PubMed ID: 8355187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The novel thromboxane A2 receptor antagonist KW-3635 abolishes the cyclic flow reduction in the canine carotid artery.
    Higo K; Karasawa A
    Biol Pharm Bull; 1994 Jul; 17(7):902-6. PubMed ID: 8000373
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibitory effect of vapiprost on contractile responses of isolated dog renal arteries to thromboxane A2 analogue, U46619.
    Sakanashi M; Matsuzaki T; Noguchi K; Nakasone J; Itomine T; Uza M; Toyama F; Higuchi M
    Gen Pharmacol; 1994 Jul; 25(4):617-22. PubMed ID: 7958719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.